IXICO plc (LSE:IXI) posted strong results for the year ended September 2025, reporting a 13% rise in revenue and a 21% improvement in EBITDA loss, reflecting continued progress under its Innovate Lead Scale strategy. The company strengthened its order book, expanded its North American presence, and further diversified its revenue mix while enhancing capabilities across its AI-enabled neuroimaging platform. These developments reinforce IXICO’s position as a leading player in neuroimaging and biomarker analytics, supporting efforts to accelerate drug development for neurological diseases and creating added value for stakeholders.
Following the announcement, IXICO’s shares rose 4%.
The company also confirmed that its Annual General Meeting will take place on 23 January 2026.
More about IXICO plc
IXICO plc is a global specialist in neuroscience imaging and biomarker analytics, leveraging an AI-driven platform to advance the understanding and treatment of neurological conditions. Operating as an Imaging Contract Research Organisation (iCRO), IXICO partners with pharmaceutical companies, biotechs, and non-profits to support clinical trials focused on disorders such as Alzheimer’s, Huntington’s, and Parkinson’s. The company provides precise imaging biomarker measurement to accelerate drug discovery and development.
Leave a Reply